YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Netflix downgraded, SanDisk initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled…
CARMIEL, Israel, Sept. 8, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare di…
Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Investor Relations - Mike Moyer President and Chief Executive Officer - Dror Bashan Senior Vice President and Chief Financial Officer - Gilad Ma…
Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance and Market Positioning Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why i…
Major earnings expected before the bell on Wednesday include: * Nebius Group N.V. (NBIS [https://seekingalpha.com/symbol/NBIS]) * Tencent Holdings Limited (TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Brinker International (EAT [https:…
Pluxee N.V. Regulated information Half-year report on Pluxee N.V.'s liquidity contract as of June 30, 2026 Pursuant to the liquidity contract entered into by Pluxee N.V. with BNP Paribas, the following assets appeared on the liquidity acco…
Pluxee N.V. Pluxee reports Q3 Fiscal 2026 performance in line with expectations and confirms its financial objectives Highlights Commercial performance on track toward full-year objectives, supported by continuous momentum in new client wi…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Pluxee’s recent performance has caught attention Pluxee (ENXTPA:PLX) has drawn fresh interest after a mixed stretch…
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance and Market Positioning Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why i…
Protalix BioTherapeutics (AMEX:PLX) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and financial da…
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Valuation snapshot and recent performance Pluxee (ENXTPA:PLX) has b…
Pluxee N.V. Regulated information Paris, April 13, 2026 DISCLOSURE FISCAL 2026/23 OF TRANSACTIONS ON TREASURY SHARES Period of: April 7 to April 10, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregat…
The market has climbed 3.4% in the last 7 days and an impressive 30% over the past year, with earnings projected to grow annually by 16%. In light of these robust market conditions, identifying stocks with strong financials becomes crucial…
Pluxee N.V. Regulated information Paris, April 7, 2026 DISCLOSURE FISCAL 2026/22 OF TRANSACTIONS ON TREASURY SHARES Period of: March 30 to April 2, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate…
Pluxee N.V. Regulated information Paris, March 30, 2026 DISCLOSURE FISCAL 2026/21 OF TRANSACTIONS ON TREASURY SHARES Period of: March 23 to March 27, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggrega…
Pluxee N.V. Regulated information Paris, March 23, 2026 DISCLOSURE FISCAL 2026/20 OF TRANSACTIONS ON TREASURY SHARES Period of: March 16 to March 20, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggrega…
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 Proactive uses images sourced from Shutterstock Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regul…
* Protalix BioTherapeutics press release [https://seekingalpha.com/pr/20442081-protalix-biotherapeutics-reports-fiscal-year-2025-financial-and-business-results] (PLX [https://seekingalpha.com/symbol/PLX]): FY GAAP EPS of -$0.08 misses by $…
Major earnings expected before the bell on Wednesday include: * Tencent Holdings Limited (TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Macy's (M [https://seekingalpha.com/symbol/M]) * General Mills (GIS [https://seekingalpha.com/symbol…
Pluxee N.V. Regulated information Paris, March 16, 2026 DISCLOSURE FISCAL 2026/19 OF TRANSACTIONS ON TREASURY SHARES Period of: March 9 to March 13, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregat…
[Quarterly Report Financial Analysis and Business Performance Review with Office Tools] Mohamad Faizal Bin Ramli/iStock via Getty Images Wall Street has entered a quieter phase of the earnings calendar, but the macro environment is shoutin…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. If you are wondering whether Pluxee is attractively priced or just a value trap, the current share price of €11.03 make…
The U.S. stock market kicked off February with a strong performance, as major indexes like the Dow Jones and S&P 500 posted significant gains. Amidst this backdrop of optimism, investors are exploring various opportunities across different…
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT CHMP Positive Opinion for Elfabrio Four-Week Dosing In October 2025, Protalix BioTherapeutics, Inc. (NYSE:PLX) announced that the Committee for Medicinal Products for Hum…
[Book with diagnosis Fabry disease and pills. Medical concept.] designer491/iStock via Getty Images Protalix BioTherapeutics (PLX [https://seekingalpha.com/symbol/PLX]) said on Friday that an expert panel of the European Medicines Agency (…
Pluxee (ENXTPA:PLX) has drawn investor attention after a sustained share price pullback, with the stock showing negative returns over the past week, month and past 3 months, prompting closer scrutiny of its current valuation. See our lates…
As the U.S. stock market experiences a surge, with major indexes like the S&P 500 reaching new all-time highs, investors are increasingly looking for opportunities beyond traditional large-cap stocks. Despite its somewhat outdated connotat…
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Protalix BioTherapeutics, Inc. (NYSE:PLX) announced a collaboration with the Germany-based Secarna Pharmaceuticals to develop novel antisense oligonucleotide (ASO) therap…
Pluxee (ENXTPA:PLX) has been sliding this year, with the share price down nearly 29% year to date, even as revenue and net income continue to edge higher. That disconnect is catching value investors attention. See our latest analysis for P…
Wondering whether Pluxee offers real value or is just another name on the stock market? You are not alone, especially as shifting valuations have caught many investors’ attention recently. There have been some dramatic moves lately, with P…
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2025 Financial and Operational Review Protalix BioTherapeutics, Inc. (NYSE:PLX) announced 3Q:25 financial and operational results in a November 13th, 2025,…
Company to host conference call and webcast today at 8:00 a.m. EST CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and c…
Pluxee’s stock has seen a modest increase in its Fair Value Estimate, rising from €22.51 to €23.07 as recent analyst updates paint a nuanced picture of the company’s prospects. A slight uptick in revenue growth projections supports this ch…
LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (“Protalix” or “the Compa…
As the United States stock market reaches record highs, driven by a tame inflation report and expectations of an interest rate cut, investors are exploring diverse opportunities across various sectors. Penny stocks, often associated with s…